A message from our sponsor.
Novo Nordisk is aiming to corner the GLP1 market. A foreign company wants to send jobs and profits overseas. And it could RAISE COSTS for American patients.
The proposed acquisition of a GLP1 manufacturer could give rise to antitrust concerns. It’s out of line with President Trump’s America First goals. Learn more.